All articles by Bikrant Kumar Singh

  1. August’s top news stories

    Retrophin’s fosmetpantotenate fails in Phase III trial for PKAN Biopharmaceutical firm Retrophin reported that the Phase III clinical trial of…
    Read More…

    5 Sep
  2. Translate Bio’s mRNA candidate produces mixed results in CF trial

    Translate Bio has reported positive interim data from a Phase I/II clinical trial of its mRNA candidate MRT5005 for the…
    Read More…

    1 Aug
  3. Daiichi Sankyo reports positive data from hypercholesterolemia study

    Daiichi Sankyo has reported findings from the Phase III clinical trial of bempedoic acid / ezetimibe fixed-dose combination (FDC) tablet…
    Read More…

    1 Aug
  4. Lilly reports improved survival in Verzenio’s MONARCH 2 trial

    Eli Lilly has reported positive findings from the Phase III MONARCH 2 clinical trial of Verzenio (abemaciclib) with fulvestrant to…
    Read More…

    31 Jul
  5. Alkermes-Biogen’s MS drug shows improved GI tolerability

    Alkermes and Biogen have reported that diroximel fumarate demonstrated a statistically superior gastrointestinal (GI) tolerability profile compared to Tecfidera (dimethyl…
    Read More…

    31 Jul
  6. Cidara reports positive data from Phase II trial of rezafungin

    Cidara Therapeutics has announced that its antifungal candidate rezafungin met all efficacy, safety, and tolerability measures in part B of…
    Read More…

    30 Jul
  7. Bellus Health starts recruitment in Phase II chronic cough trial

    Canadian biopharmaceutical firm Bellus Health has commenced patient enrolment in the Phase II RELIEF clinical trial of BLU-5937 to treat…
    Read More…

    30 Jul
  8. Keytruda improves response in late-stage breast cancer study

    Merck has reported positive results from the Phase III KEYNOTE-522 clinical trial of Keytruda in combination with chemotherapy for the…
    Read More…

    30 Jul
  9. Oryzon closes enrolment in vafidemstat’s Phase IIa trials

    Spain-based Oryzon Genomics has completed patient enrolment in the Phase IIa REIMAGINE and REIMAGINE-AD clinical trials of vafidemstat. The REIMAGINE…
    Read More…

    30 Jul
  10. PARAGON-HF study by Novartis misses primary goal

    Novartis has reported that the Phase III PARAGON-HF clinical trial of sacubitril/valsartan for heart failure patients with preserved ejection fraction…
    Read More…

    29 Jul
Close
Close
Close

Go Top